Substituted 2-(3′,4′,5′-trimethoxybenzoyl)-benzo[b] thiophene derivatives as potent tubulin polymerization inhibitors

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 14, 2010, Pages 5114-5122

  Romagnoli, Romeo ^a   Baraldi, Pier Giovanni ^a   Carrion, Maria Dora ^a   Cruz Lopez, Olga ^a   Tolomeo, Manlio ^b   Grimaudo, Stefania ^b   Cristina, Antonietta Di ^b   Pipitone, Maria Rosaria ^b   Balzarini, Jan ^c   Brancale, Andrea ^d   Hamel, Ernest ^e  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antiproliferative agents; Antitumor; Microtubules; Tubulin polymerization inhibitors

Indexed keywords

(4 METHOXY 4 METHYLBENZO[B]THIOPHEN 2 YL)(3,4,5 TRIMETHOXYPHENYL)METHANONE; 2 (3',4',5' TRIMETHOXYBENZOYL) 3 AMINOBENZO[B]THIOPHENE; ANTINEOPLASTIC AGENT; BENZENE; BENZOTHIOPHENE DERIVATIVE; METHYL GROUP; TUBULIN POLYMERIZATION INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DIVISION; CELL STRAIN K 562; CONTROLLED STUDY; DRUG SCREENING; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; MITOSIS; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANISOLES; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MODELS, MOLECULAR; NEOPLASMS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES; TUBULIN; TUBULIN MODULATORS;

EID: 77955319048     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2010.05.068     Document Type: Article

References (30)

1. L. Worderman, and T.J. Mitchison Dynamics of Microtubule Assembly In vivo J. Hyams, C. Lloyd, Microtubules 1994 Wiley-Liss, Inc New York
2. B.R. Hearn, S.J. Shaw, and D.C. Myles Compr. Med. Chem. II 7 2007 81
3. E. Pasquier, N. Andr, and D. Braguer Curr. Cancer Drug Targets 7 2007 566
4. F. Pellegrinelli, and D.R. Budman Cancer Invest. 23 2005 264
5. D.J. Chaplin, M.R. Horsman, and D.W. Siemann Curr. Opin. Invest. Drugs 7 2006 522
6. C.E. Walczak Curr. Opin. Cell Biol. 12 2000 52
7. J.A. Hadfield, S. Ducki, N. Hirst, and A.T. McGown Prog. Cell Cycle Res. 5 2003 309
8. S. Ducki Anticancer Agents Med. Chem. 9 2009 336
9. A. Kiselyov, and K.V. Bulakin Anticancer Agents Med. Chem. 7 2007 189
10. G.R. Pettit, S.B. Singh, E. Hamel, C.M. Lin, D.S. Alberts, and D. Garcia-Kendall Experientia 45 1989 209
11. C.M. Lin, H.H. Ho, G.R. Pettit, and E. Hamel Biochemistry 28 1989 6984
12. G.C. Tron, T. Pirali, G. Sorba, F. Pagliai, S. Busacca, and A.A. Genazzani J. Med. Chem. 49 2006 3033
13. N. Mahindroo, J.P. Liou, J.Y. Chang, and H.P. Hsieh Expert Opin. Ther. Patents 16 2006 647
14. A. Chaudhary, S.N. Pandeya, P. Kumar, P.P. Sharma, S. Gupta, N. Soni, K.K. Verma, and G. Bhardwaj Mini-Rev. Med. Chem. 7 2007 1186
15. H.P. Hsie, J.P. Liou, and N. Mahindroo Curr. Pharm. Des. 11 2005 1655
16. K.G. Pinney, A.D. Bounds, K.M. Dingerman, V.P. Mocharla, G.R. Pettit, R. Bai, and E. Hamel Bioorg. Med. Chem. Lett. 9 1999 1081
17. B.L. Flynn, P. Verdier-Pinard, and E. Hamel Org. Lett. 3 2001 651
18. R. Romagnoli, P.G. Baraldi, M.D. Carrion, C. Lopez Cara, D. Preti, F. Fruttarolo, M.G. Pavani, M.A. Tabrizi, M. Tolomeo, S. Grimaudo, C. Di Antonella, J. Balzarini, J.A. Hadfield, A. Brancale, and E. Hamel J. Med. Chem. 50 2007 2273
19. R. Romagnoli, P.G. Baraldi, M.K. Jung, M.A. Iaconinoto, M.D. Carrion, D. Preti, M.A. Tabrizi, F. Fruttarlo, E. De Clercq, J. Balzarini, and E. Hamel Bioorg. Med. Chem. Lett. 15 2005 4048
20. For a review on the mechanism and application of Newman-Kwart rearrangement see: G.C. Lloyd-Jones, J.D. Moseley, and J.S. Renny Synthesis 5 2008 661
21. J.R. Beck J. Heterocycl. Chem. 15 1978 513
22. E. Hamel Cell Biochem. Biophys. 38 2003 1
23. P. Verdier-Pinard, J.-Y. Lai, H.-D. Yoo, J. Yu, B. Marquez, D.G. Nagle, M. Nambu, J.D. White, J.R. Falck, W.H. Gerwick, B.W. Day, and E. Hamel Mol. Pharmacol. 53 1998 62
24. C.B. Lozzio, and B.B. Lozzio Blood 45 1975 321
25. G. Viola, D. Vedaldi, F. Dall'acqua, E. Fortunato, G. Basso, N. Bianchi, C. Zuccato, M. Borgatti, I. Lampronti, and R. Gambari Biochem. Pharmacol. 75 2008 810
26. R. Romagnoli, P.G. Baraldi, M.D. Carrion, C. Lopez-Cara, O. Cruz-Lopez, M. Tolomeo, S. Grimaudo, A. Di Cristina, M.R. Pipitone, J. Balzarini, N. Zonta, A. Brancale, and E. Hamel Bioorg. Med. Chem. 17 2009 6862
27. E. Hamel, and C.M. Lin Biochemistry 23 1984 4173
28. R.B.G. Ravelli, B. Gigant, P.A. Curmi, I. Jourdain, S. Lachkar, A. Sobel, and M. Knossow Nature 428 2004 198
29. Molecular Operating Environment (MOE 2007.09). Chemical Computing Group, Inc. Montreal, Quebec, Canada. http://www.chemcomp.com.
30. FlexX 3.0. BioSolveIT GmbH, Sankt Augustin, Germany. http://www. biosolveit.de.